Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Despite vaccine progress, investors eye Fed support as coronavirus surges

11/17/2020 | 09:12am EST

NEW YORK, Nov 17 (Reuters) - Investors are weighing the chances the Federal Reserve will increase its purchases of U.S. government debt in coming weeks to counteract the economic fallout of a COVID-19 resurgence, an intervention that could reverse a recent rise in Treasury yields to multi-month highs.

News that two coronavirus vaccines proved highly effective in late-stage trials in recent days have stoked investors' appetite for risk, sending yields, which move inversely to bond prices, to their highest levels since March and U.S. stock markets to record highs.

Still, some investors believe that rising coronavirus cases may threaten the fragile U.S. economic recovery at a time when fiscal stimulus is likely to be delayed and widespread access to a vaccine remains months away. The United States recorded more than 1 million new COVID-19 cases last week.

That combination of negative factors could push the central bank to increase its support, some investors argue, even though asset purchases already stand at record levels and the Fed has not indicated it intends to raise them at its next two-day policy meeting, Dec. 15-16. Fed Chairman Jerome Powell is slated to speak Tuesday afternoon, and investors will be listening carefully for any insight into the Fed's thinking.

Steve Englander, head of global G10 FX research and North America macro strategy at Standard Chartered, believes the Fed may surprise markets by increasing its asset purchases to $120 billion a month before the December meeting if it appears that rising COVID-19 cases are weighing on the economy.

The Fed has bought at least $80 billion a month since the start of the pandemic.

The Fed "may feel like it needs to act, even if they expect the vaccine to come," Englander said. "It looks like there will be a two- or three-month period before the vaccine is widely available that looks like it will be really, really painful."

An increase in bond purchases would likely drag the benchmark 10-year Treasury yield to the bottom of its 0.5% to 1% range, he said.

The Fed may also be forced to adjust its Treasury purchases if the positive vaccine news pushes the 10-year yield above 1%, said Priya Misra, global head of rates strategy at TD Securities. Misra expects the Fed to continue to buy the same amount of Treasury debt, but believes it will increase the portion of longer-dated bonds it buys.

Rising yields are a potential problem for the Fed because they raise the cost of borrowing for companies and individuals, something that could threaten economic growth.

"I think if you break 1% on (10-year yields) in quick fashion, you could see the Fed do it before the December meeting," Misra said.

The 10-year-yield was at 0.911% on Monday, after Moderna Inc earlier in the day announced promising results from its vaccine trials. The benchmark yield hit a high of 0.975% last week after Pfizer Inc announced similar results for its vaccine.

Analysts at JPMorgan on Monday said in a note that they expect the Fed to increase the average maturity of its Treasury holdings at its December meeting, which could push yields lower.

Fed Vice Chair Richard Clarida in a speech Monday gave no direct indication that the central bank was on course to boost its purchases. Some investors are taking the Fed at their word.

"The markets are functioning well and unless we see the need for additional lockdowns or closures, I think that they won't make any big moves before the end of the year," said Kevin Giddis, head of fixed income at Raymond James.

But even if the near-term picture appears benign, some investors believe the Fed will step up its asset purchases as a precaution.

"My view is the Fed will increase (bond purchases) to $160 billion a month in December even if we have good news on the vaccine front and irrespective of what the news is regarding economic recovery," said Thomas Costerg, senior economist at Pictet Wealth Management in Geneva. "They have learned their lessons from the past experience." (Reporting by Kate Duguid in New York; Additional reporting by Sujata Rao in London; Editing by Ira Iosebashvili and Leslie Adler)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
JPMORGAN CHASE & CO. -1.25% 132.12 Delayed Quote.5.29%
MODERNA, INC. 12.20% 147 Delayed Quote.40.71%
PFIZER INC. 2.00% 37.28 Delayed Quote.1.28%
RAYMOND JAMES FINANCIAL -1.83% 100.17 Delayed Quote.4.70%
STANDARD CHARTERED PLC 1.52% 461.7 Delayed Quote.-2.36%
All news about MODERNA, INC.
02:46aGermany backs EU export restrictions on vaccine after supply cuts
02:41aASTRAZENECA : COVID-19 vaccine supplies continue to be tight, UK minister says
02:25aCOVID : Uk vaccine minister zahawi says moderna confident of delivering vaccines..
01/25EXCLUSIVE : Scarce niche syringes complicate U.S. plan to squeeze more COVID sho..
01/25MARKET CHATTER : Tata Group Talks With Moderna to Launch COVID-19 Vaccine in Ind..
01/25Canadian gaming CEO resigns after being accused of flouting COVID-19 rules
01/25MODERNA : U.S. CDC says 41.4 mln doses of COVID-19 vaccines distributed, 22.7 ml..
01/25Scarce niche syringes complicate U.S. plan to squeeze more COVID shots from P..
01/25Health Care Up As Investors Rotate Back Into Biotech -- Health Care Roundup
01/25CLOSE UPDATE : Stocks Start Week Mixed in Shaky Session Ahead of Earnings Week
More news
Financials (USD)
Sales 2020 512 M - -
Net income 2020 -571 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -120x
Yield 2020 -
Capitalization 58 169 M 58 169 M -
EV / Sales 2020 109x
EV / Sales 2021 5,05x
Nbr of Employees 1 100
Free-Float 90,0%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137,27 $
Last Close Price 147,00 $
Spread / Highest target 25,9%
Spread / Average Target -6,62%
Spread / Lowest Target -53,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
SEAGEN INC.2.84%32 583